Form 990 for tax year 2023

Totals

Total revenue

$641,068

Total expenses

$1,154,712

Contributions and grants received

$657,576

Grants paid

$511,773

Program service revenue

$0

Investment income

$71,862

Other revenue

-$88,370

Total assets, end of year

$2,075,323

Total liabilities, end of year

$145,667

Net assets or fund balances, end of year

$1,929,656

Program services expenses (Part IX)

$731,842

Management and general expenses

$189,417

Fundraising expenses

$233,453

Program service expenses (Part III)

$731,842

Program services were 63.4% of total expenses calculated — Part IX's program-services column over total expenses, both as filed.

Line items

Every line the filer filed in Parts VIII, IX and X, as filed and in filed order. Blank columns are left out, and the lines are not forced to add up to the totals above.

Mission and programs · 2023

• SKC AND OUR ADVISORS SURVEY, ACTIVELY DISCUSS, AND PRIORITIZE THE AREAS OF GREATEST UNMET NEEDS WITHIN THE PEDIATRIC CANCER RESEARCH LANDSCAPE AND DEVELOP SPECIFIC PROGRAMS TO ADDRESS THEM. (1) THE PH I TITAN CLINICAL TRIAL IS PROVIDING AN EFFECTIVE TARGETED DRUG FOR CHILDREN WITH ALK MUTATIONS IN FRONTLINE TREATMENT WHEN NEWLY DIAGNOSED AND IS GENERATING CRITICAL DATA TOWARDS AN APPROVAL FOR USE AS A STANDARD OF CARE. WORKING TOWARDS HAVING THIS BE ONE OF THE FIRST TARGETED AGENTS BECOMING APPROVED FOR HR NB AND UTILIZED AS A COMBINATION THERAPY STRATEGY, MAKING A SIGNIFICANT IMPACT ON OVERALL SURVIVAL. (2) OUR COLLABORATION WITH THE NATIONAL CANCER INSTITUTE TO VALIDATE AND DEVELOP AN IMMUNOTHERAPY TREATMENT FOR CHILDREN WITH ETMR AND MEDULLOBLASTOMA BRAIN TUMORS USING A T CELL CAR TO TARGET GPC2 IS THE FIRST EVER IMMUNOTHERAPY RESEARCH PROGRAM SPECIFIC FOR ETMR BRAIN TUMORS. IF THE RESULTS ARE POSITIVE THIS WORK WILL BE RAPIDLY TRANSLATED INTO A CLINICAL TRIAL TO INCLUDE CHILDREN WITH ETMR AS WELL AS MEDULLOBLASTOMA USING THIS CUTTING-EDGE IMMUNOTHERAPY. (3) THE PH I CLINICAL TRIAL USING A TRIPLET COMBINATION HAS BEEN A LIFELINE FOR CHILDREN WITH NEUROBLASTOMA WHO RELAPSE AND THE STUDY HAS BEEN SO SUCCESSFUL THAT IT WILL STAY OPEN TO ACCRUE EVEN MORE PATIENTS THAN ORIGINALLY PLANNED. WHILE THE CLINICAL TRIAL IS PROVIDING TREATMENT BENEFIT TO PATIENTS, THE TRIAL IS GENERATING VERY IMPORTANT DATA THAT CAN BE USED TO FURTHER ADVANCE THIS TRIPLE TREATMENT COMBINATION INTO MORE POINTS IN THE TREATMENT CONTINUUM FOR EVEN GREATER PATIENT BENEFIT. (4) SKC TARGETS ONLY THE MOST CHALLENGING AND POOREST OUTCOME CHILDHOOD CANCERS THAT REQUIRE SIGNIFICANT HELP AND HAVE THE GREATEST UNMET NEED INCLUDING HIGH-RISK BRAIN TUMORS AND SOLID TUMORS. (5) TAKES A GLOBAL APPROACH TO SUPPORTING PROGRAMS TO LEVERAGE THE COLLECTIVE POWER OF COLLABORATION ACROSS SEVERAL CENTERS-OF-EXCELLENCE TO BREAK DOWN BARRIERS, SPEED PROGRESS AND HAVE MORE CHILDREN ACCESS PROMISING TREATMENTS. (6) PRIORITIZES ADVANCING TREATMENT OPTIONS THAT HAVE THE HIGHEST POTENTIAL FOR CURATIVE RESPONSES RATHER THAN PARTIAL TUMOR SHRINKAGE OR TEMPORARY LIFE EXTENSION. (7) TAKES LEADERSHIP ROLES WITHIN INFLUENTIAL NATIONAL AND INTERNATIONAL RESEARCH GROUPS' ADVISORY BOARDS AND CO-AUTHOR INFLUENTIAL PAPERS IN PROFESSIONAL JOURNALS TO DRIVE NEW DIRECTION TO POSITIVELY IMPACT PATIENTS. (8) BUILD COALITIONS AND PARTNERSHIPS WITH OTHER NONPROFITS IN COLLABORATIVELY DRIVING AND FUNDING RESEARCH PROJECTS FOR GREATER IMPACT AND SCALE BECAUSE WE ARE MUCH MORE EFFECTIVE TOGETHER THAN WORKING ALONE. SKC PRIORITIZES THE DELIVERY OF TRANSFORMATIVE, NEXT-GENERATION CANCER THERAPIES TO THIS POPULATION THAT INCLUDES IMMUNOTHERAPY, VACCINES, CELLULAR THERAPY, ONCOLYTIC VIROTHERAPY, THERAPEUTIC ANTIBODIES, CHECKPOINT INHIBITORS, SYNERGISTIC COMBINATION TREATMENTS, NEW GENOMICALLY TARGETED DRUGS, INTERVENTIONAL RADIOLOGY TECHNIQUES AND NOVEL DELIVERY MECHANISMS. OUR CRITERIA FOR IDENTIFYING AND SUPPORTING THESE NOVEL APPROACHES AIMS TO PROVIDE MORE EFFECTIVE AND LESS TOXIC TREATMENT OPTIONS THAN THE CURRENT STANDARD-OF-CARE. (9) WE ARE PLANNING A NEW INITIATIVE FOR MEDULLOBLASTOMA TO IDENTIFY PROMISING COMBINATION THERAPIES THAT CROSS THE BLOOD-BRAIN BARRIER AS WELL AS NEW DELIVERY MECHANISMS.

  Expenses $731,842 · Grants $511,773

As filed on the 2023 return. The filer continues this part on Schedule O, which is not shown here.

Listed in Part VII

Compensation is as filed in Part VII: reportable pay from this organization and from related organizations, other compensation, and hours per week. The total, marked calculated, is our sum of the three dollar columns, with a blank column counted as $0; the form itself has no total. On a Form 990-EZ the columns are Part IV's instead, and on a Form 990-PF Part VIII's — compensation, contributions to benefit plans, and expense account — and the total sums those. A Schedule J breakdown is as filed: base pay, bonus, other, deferred compensation and nontaxable benefits from this organization, with any from related organizations beside each, and the filer's own total. It is shown with the Part VII listing of the same name on the same return. The form gives no key between the two, so that pairing is ours, and is marked matched by us.

Schedule J

Part I's answers as filed. A line not listed was left unanswered; on lines 1a and 3 that means the box was not checked.

Grants on this return

• CHILDREN'S HOSPITAL OF PHILADELPHIA

  $162,500

  CANCER RESEARCH

• THE REGENTS OF THE UNIVERSITY OF CA

  $150,000

  CANCER RESEARCH

• THE SWIFTY FOUNDATION

  $95,000

  CANCER RESEARCH

• NATIONAL CANCER INSTITUTE

  $47,000

  CANCER RESEARCH

• WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY

  $6,228

  CANCER RESEARCH

• COLUMBIA UNIVERSITY

  $5,068

  CANCER RESEARCH

Provenance

Return type

form_990

Tax year

2023

Filed

13 November 2024

IRS schema version

2023v5.0

Source object

202443199349312329

Check it against the return as filed: the GivingTuesday Data Lake hosts a public copy of the original XML.

The source document this was parsed from is served over the API, which is where bulk and document access live.